Ciplox tablet kya hai?
Ciplox ek ciprofloxacin wali fluoroquinolone antibiotic tablet hai, jo sirf gambhir ya uchch-jokhim bakteriayi infections (jaise pyelonephritis/upper UTI, prostatitis, tularemia, anthrax PEP) mein, jab behtar vikalp upyukt na hon, tab istemal karni chahiye—kyunki isse gambhir side-effects aur resistance ka khatra badhta hai. 1, 2, 3, 4, 5
Kab istemal karein (morbidity–mortality–QOL ko dhyan mein rakhkar)
- Pyelonephritis ya prostatitis (mild–moderate), agar local fluoroquinolone resistance ≤10% ho: ciprofloxacin preferred; warna pehle ek IV long-acting dose (jaise ceftriaxone) dekar tailor karein. 3, 2
- Tularemia: CDC (2025) ke mutabik ciprofloxacin first-line effective vikalp. 4
- Inhalational anthrax post-exposure prophylaxis: ciprofloxacin 500 mg BID 60 din tak (vaccine ke saath). 5
Kab na dein / saavdhaniyan
- Asaan lower UTI (cystitis) ke liye pehli pasand nahi; nitrofurantoin/AMC/TMP-SMX ko tarjeeh. Fluoroquinolones ko reserve rakhein taaki resistance aur serious AEs kam hon. 3, 2
- Bachche (<18 saal): sirf vishesh gambhir indications (complicated UTI/anthrax PEP). 1
- Pregnancy/breastfeeding: anthrax PEP mein chal sakta hai; anya sthitiyon mein risk–benefit sakht nazar se. 5
- Tizanidine ke saath bilkul na dein; steroids/umr >60/tendon history mein tendon rupture ka zyada khatra. 1
- High local FQ resistance (>10% UTI pathogens) ho to monotherapy se bachien. 3
Typical dosing (adult)
- Pyelonephritis/prostatitis (outpatient, resistance ≤10%): 500 mg PO 12-hourly 7 din (ER 1000 mg OD 7 din bhi viklap). Agar resistance >10% sandigdh ho to shuruaat mein 1 g ceftriaxone IV ek baar. 3
- Tularemia: 750 mg PO 12-hourly (guideline doses per CDC). 4
- Anthrax PEP: 500 mg PO 12-hourly, 60 din. 5
Aam pitfalls aur unse bachav
- Uncomplicated cystitis mein jaldi se FQ shuru kar dena—isse resistance/QOL harm badhta hai; pehle narrow-spectrum agents chunen. 3, 2
- Tizanidine co-use, dairy/antacids/iron ke saath dena (absorption ghatta hai); dose se 2–4 ghante alag rakhen. 1
- Tendon dard/soojan ko ignore na karein—turant band karein aur vikalp antibiotic par switch karein. 1
Evidence strength and recency:
- WHO 2024 AWaRe: upper UTI/prostatitis mein ciprofloxacin first-choice (agar AMR allow kare), lower UTI ke liye nahi. 2
- IDSA/ESCMID 2011: pyelonephritis mein ciprofloxacin effective; cystitis mein FQ ko reserve rakhen. 3
- CDC 2025 tularemia: ciprofloxacin first-line supported. 4
- FDA Label 2026: safety contraindications/warnings definitive. 1